BU 224

Drug Profile

BU 224

Latest Information Update: 21 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Analgesics; Antidementias; Neuroprotectants; Small molecules
  • Mechanism of Action Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 04 Mar 2003 No development reported - Preclinical for Pain in USA (unspecified route)
  • 29 Nov 2000 Preclinical development for Pain in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top